ADMP News and Press, Adamis Pharmaceuticals Corporation From 10/12/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com It’s time for another dive into the biggest pre-market stock movers as we check out shares on Wednesday! Moving stocks this morning are clinical trials, special dividend...

Adamis Pharmaceuticals ( NASDAQ: ADMP ) has begun a review of strategic and financing alternatives that could include a sale of the company or its marketed products. Other potential options are a merger, reverse merger, and/or seek additional financing. Shares are ...

SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammato...

Summary Adamis Pharmaceuticals recently provided an update on Tempol’s Phase II/III COVID-19 trial, which revealed the interim did not demonstrate statistical significance of its primary endpoint. The DSMB has recommended the company halt the trial. The company believes vac...

Adamis Pharmaceuticals ( NASDAQ: ADMP ) said Wednesday that the company’s experimental COVID-19 therapy Tempol did not achieve the primary endpoint in a Phase 2/3 clinical trial that involved high-risk subjects with early COVID-19 infection. The study, designed to e...

Interim data from the Phase 2/3 clinical trial of Tempol did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo Independent Data Safety Monitoring Board recommends halting the trial ...

The clinical trial of Tempol has reached the initial planned enrollment of 248 subjects Independent Data Monitoring Board to review interim data from approximately 200 initial subjects SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporati...

SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2022 Annual Meeting of Stockholders (“Annual Meeting”) was convened, as scheduled. At the Annual Meeting, all items of business were considered, with the...

Adamis Pharmaceuticals Corporation (ADMP) Q2 2022 Earnings Conference Call August 10, 2022 04:30 PM ET Company Participants Robert Uhl - Managing Director, ICR Westwicke David J. Marguglio - Chief Executive Officer David Benedicto - Chief Financial Officer Ro...

SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inf...